A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab in an Unsupervised Setting, Using Either an Auto-Injector or a Prefilled Syringe
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2018
At a glance
- Drugs Fasinumab (Primary)
- Indications Pain
- Focus Registrational; Therapeutic Use
- Acronyms FACT DEVICE
- Sponsors Regeneron Pharmaceuticals
- 06 Sep 2018 Planned End Date changed from 6 Apr 2020 to 27 Jul 2020.
- 06 Sep 2018 Planned initiation date changed from 1 Oct 2018 to 10 Dec 2018.
- 30 May 2018 Planned End Date changed from 9 Dec 2019 to 6 Apr 2020.